“Drug Development for Blood Disorders” was moderated by Kristen Kluska and featured Dr. Hugh Young Rienhoff, Jr. M.D., Founder & CEO of Imago BioSciences, Inc. and Raul Rodriguez, President & CEO of Rigel Pharmaceuticals Inc.
• Imago BioSciences highlighted its lead program, bomedemstat, which is an LSD1 inhibitor being evaluated in select cancers and bone marrow diseases.
• Rigel Pharmaceuticals walked through the opportunities of its lead program, TAVALISSE (fostamatinib), which is currently approved for chronic immune thrombocytopenia and for olutasidenib, which has a PDUFA date of February 15, 2023.
#Cantorconferenceseries #Oncology #Hematology #Hemeonc #Cantorfitzgerald #Cantorhealthcare